Literature DB >> 23774691

A new mutation that predicted a drastic alteration of the BTK protein function.

Anne Debost-Legrand1, Guillaume Legrand, Gaelle Moulillot, Christine Francannet, Bertrand Bocly, Ioannis Theodoroub, Catherine Paillard.   

Abstract

X-linked agammaglobulinemia (XLA) or Bruton disease is a relatively rare constitutionally immune disorder due to a genetic mutation of BTK (Bruton tyrosine kinase) gene which encodes for BTK protein. BTK is a signal-transducing protein expressed in hematopoietic lineages. The genetic disorder is responsible for B cell lymphocytes' maturation arrest. The humoral immunodeficiency caused by BTK mutation is linked with recurrent bacterial and viral infections. Genetic investigations of the prepositus as well as the other members of the family are necessary to characterize a mutation in BTK gene to confirm the diagnosis and reveal a hereditary transmission or de novo mutation. Authors propose and comment a case report of an 8 month old child who suffers from Bruton disease. Initial presentation was neutropenia, but genetic investigation has revealed a previously non-reported mutation in the BTK gene. The same mutation was found in the mother with low expression of BTK in monocytes and normal in B-cells suggesting a lineage specific extinction of BTK which has never been reported before.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APC; Allophycocyanin; B-Cell Receptor; BCR; BTK; BTK gene; Bruton Tyrosine Kinase; Bruton tyrosine kinase; FITC-conjugated; Fluorescein Isothiocyanate-conjugated; Neutropenia; PBMC; PH; PI3K; PIP(3); Peripheral Blood Mononuclear Cell; Phosphatidylinositide 3-Kinases; Phosphatidylinositol (3,4,5)-Trisphosphate; Pleckstrin Homology; SH2; SH3; Scr Homology 3; Src Homology 2; TH; Tec Homology; X-Linked Agammaglobulinemia; X-linked agammaglobulinemia; XLA

Mesh:

Substances:

Year:  2013        PMID: 23774691     DOI: 10.1016/j.gene.2013.05.070

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  3 in total

Review 1.  An update on the use of immunoglobulin for the treatment of immunodeficiency disorders.

Authors:  Stephanie Albin; Charlotte Cunningham-Rundles
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

2.  Clinical characteristics and prenatal diagnosis for 22 families in Henan Province of China with X-linked agammaglobulinemia (XLA) related to Bruton's tyrosine kinase (BTK) gene mutations.

Authors:  Shanshan Gao; Shuang Hu; Huikun Duan; Li Wang; Xiangdong Kong
Journal:  BMC Med Genet       Date:  2020-06-17       Impact factor: 2.103

3.  A novel Bruton's tyrosine kinase gene (BTK) missense mutation in a Chinese family with X-linked agammaglobulinemia.

Authors:  Bixia Zheng; Yayuan Zhang; Yu Jin; Haiguo Yu
Journal:  BMC Pediatr       Date:  2014-10-15       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.